Magnesium reduces myocardial infarct size via enhancement of adenosine mechanism in rabbits

Cardiovascular Research

Volumn 54, Issue 3, 2002, Pages 568-575

  Matsusaka, Tomoyuki ^a   Hasebe, Naoyuki ^a   Jin, Yin Tie ^a   Kawabe, Junichi ^a   Kikuchi, Kenjiro ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Adenosine; Calcium (cellular); Infarction; Ischemia; Reperfusion

Indexed keywords

8 PHENYLTHEOPHYLLINE; ADENOSINE; ALPHA,BETA METHYLENEADENOSINE DIPHOSPHATE; CALCIUM; MAGNESIUM SULFATE; TRIPHENYLTETRAZOLIUM;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; HEART ARRHYTHMIA; HEART INFARCTION SIZE; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REPERFUSION; INCIDENCE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REGULATORY MECHANISM; RISK ASSESSMENT;

5'-NUCLEOTIDASE; ADENOSINE; ADENOSINE DIPHOSPHATE; ANALYSIS OF VARIANCE; ANIMALS; CALCIUM; DRUG SYNERGISM; ENZYME INHIBITORS; MAGNESIUM; MALE; MODELS, ANIMAL; MYOCARDIAL INFARCTION; MYOCARDIUM; RABBITS; RECEPTORS, PURINERGIC P1; THEOPHYLLINE;

EID: 0036267901     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00253-5     Document Type: Article

References (46)

1. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: The second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2)
2. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction
3. Efficacy of intravenous magnesium in acute myocardial infarction in reducing arrhythmias and mortality. Meta-analysis of magnesium in acute myocardial infarction
4. Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy
5. Magnesium sulfate reduces myocardial infarct size when administered before but not after coronary reperfusion in a canine model
6. An experimental model examining the role of magnesium in the therapy of acute myocardial infarction
7. Timing of magnesium therapy affects experimental infarct size
8. Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia
9. Effects of ischemia, preconditioning, and adenosine deaminase inhibition on the interstitial adenosine levels and infarct size
10. 5′-Nucleotidase: Molecular structure and functional aspects
11. Ischemic preconditioning increases adenosine release and 5′-nucleotidase activity during myocardial ischemia and reperfusion in dogs. Implications for myocardial salvage
12. 5′-nucleotidase form rat heart
13. Magnesium. Nature's physiologic calcium blocker
14. Treatment of torsade de pointes with magnesium sulfate
15. Magnesium treatment of ventricular arrhythmias
16. Adenosine blockade during reperfusion reverses the infarct limiting effect in preconditioned canine hearts
17. Ecto-5′-nucleotidase is not required for ischemic preconditioning in rabbit myocardium in situ
18. Inotropic responsiveness of the heart in catecholamine cardiomyopathy
19. Serum 5′-nucleotidase in patients with tumor in the liver
20. Protein measurement with Folin phenol reagent
21. Is there a place for magnesium in the treatment of acute myocardial infarction?
22. Magnesium in acute myocardial infarction: Overview of available evidence
23. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. The European Cooperative Study Group
24. Evaluation of the effect of azapropazone on neutrophil migration in regional myocardial ischaemia/reperfusion injury in rabbits
25. Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbits
26. Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning
27. The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury
28. Role of adenosine receptor activation in myocardial infarct size limitation by ischaemic preconditioning
29. The rationale of magnesium supplementation in acute myocardial infarction. A review of the literature
30. Calcium overload and cardiac myocyte cell damage induced by arachidonate lipoxygenation
31. Preischaemic as well as postischaemic application of a Na+/H+ exchange inhibitor reduces infarct size in pigs
32. Rabbit hearts for the critical evaluation of drugs to reduce the size of experimentally produced acute myocardial infarction
33. Effects of antiplatelet and calcium antagonist drugs on infarct size in rats
34. The effect of two different diltiazem treatments on infarct size in ischemic, reperfused porcine hearts
35. Cardioprotective effects of amlodipine in the ischemic-reperfused heart
36. Inhibition by magnesium of calcium inward current in heart ventricular muscle
37. Internal free magnesium modulates the voltage dependence of contraction and Ca transient in rabbit ventricular myocytes
38. 2+, adenine nucleotide, and calmodulin
39. 2+, and adenine nucleotides under normal and simulated ischemic conditions
40. 2+, ionic strength and pH
41. Myocardial recovery during post-ischaemic reperfusion: Effects of nifedipine, calcium and magnesium
42. Magnesium deficiency and myocardial infarct size in the dog
43. Acute myocardial infarction, reperfusion injury, and intravenous magnesium therapy: Basic concepts and clinical implications
44. Stress and magnesium metabolism in coronary artery disease
45. Magnesium deficiency and myocardial infarct size in the dog
46. Intravenous magnesium in acute myocardial infarction